Scalper1 News
GW Pharmaceuticals (GWPH) stock vaulted Tuesday after the company said that its marijuana-derived drug candidate showed positive “proof of concept” against schizophrenia. GW Pharmaceuticals said that its study of 88 schizophrenics found that those who took its drug cannabidiol in addition to antipsychotic drugs showed improvement in symptoms, relative to the placebo group, on a few different psychiatric scales. GW said that the results looked Scalper1 News
Scalper1 News